CL2011002444A1 - Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma. - Google Patents

Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma.

Info

Publication number
CL2011002444A1
CL2011002444A1 CL2011002444A CL2011002444A CL2011002444A1 CL 2011002444 A1 CL2011002444 A1 CL 2011002444A1 CL 2011002444 A CL2011002444 A CL 2011002444A CL 2011002444 A CL2011002444 A CL 2011002444A CL 2011002444 A1 CL2011002444 A1 CL 2011002444A1
Authority
CL
Chile
Prior art keywords
liposome
eribulin
manufacturing
active compound
internal phase
Prior art date
Application number
CL2011002444A
Other languages
English (en)
Inventor
Hiroshi Kikuchi
Kenji Hyodo
Hiroshi Ishihara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66221437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2011002444A1 publication Critical patent/CL2011002444A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica que contiene un liposoma y el compuesto activo eribulina, o su sal farmacológicamente permisible, en la fase interna del liposoma; y método de manufactura de la composición del liposoma.
CL2011002444A 2009-03-30 2011-09-30 Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma. CL2011002444A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16465309P 2009-03-30 2009-03-30
JP2009082521 2009-03-30

Publications (1)

Publication Number Publication Date
CL2011002444A1 true CL2011002444A1 (es) 2012-04-09

Family

ID=66221437

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002444A CL2011002444A1 (es) 2009-03-30 2011-09-30 Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma.

Country Status (2)

Country Link
CL (1) CL2011002444A1 (es)
RU (1) RU2476216C1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161157T1 (hr) 2009-03-30 2016-11-18 Eisai R&D Management Co., Ltd. Liposomski pripravak
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
IL266198B2 (en) * 2016-10-28 2023-11-01 Servier Lab Liposomal formulation for use in cancer treatment
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
HU227912B1 (en) * 1998-06-17 2012-05-29 Eisai R & D Man Co Halichondrin analogs and methods of their use and preparation

Also Published As

Publication number Publication date
RU2476216C1 (ru) 2013-02-27

Similar Documents

Publication Publication Date Title
PE20151519A1 (es) Composicion de liposoma
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
CL2013000437A1 (es) Forma de dosificacion farmaceutica con resistencia a la rotura de al menos 500 n, que contiene un ingrediente activo, 5 al 70 % en peso de una sal inorganica, al menos 30% en peso de un oxido de polialquileno, en donde el ingrediente activo esta integrado en una matriz de liberacion controlada que comprende la sal inorganica y el oxido de polialquileno.
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
IN2015DN00185A (es)
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
CO6362012A2 (es) Clohidarto de nalmefeno dihidratado
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CL2011002862A1 (es) Uso de perhexilina o una sal farmaceuticamente aceptable de la misma para preparar un medicamento util en el tratamiento de miocardiopatia hipertrofica (mch).
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
NI201200086A (es) Composición farmacéutica que comprende un agonista de glp - 1 y metionina
AR086395A1 (es) Envase para el tratamiento de patologias
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
GT201400042A (es) Compuesto de benzotiazolona
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол
UY31856A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antiflamatorio, no esteroideo y un derivado de colchicosido
CL2010001230A1 (es) Metodo para inhibir la melanogenesis que comprende administrar un compuesto esteroidal; composicin farmaceutica; formulacion topica, util en el tratamiento de una enfermedad o condicion que involucra melanogenesis.
CO6511242A2 (es) Combinación y composición que contiene un antimicrobiano, un glucocorticoide y un antimicótico